The global surface protein gp 120 market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in March 2021, Gilead Sciences Inc. and Merck have jointly entered into a partnership to co-develop and co-commercialize the long-acting and investigational treatment combinations of Lenacapvir and Islatravir in HIV. According to the agreement, Gilead and Merck Sharp & Dohme (Merck &Co) will share operational responsibilities as well as development, marketing costs, and future revenues. According to Merck &Co, this partnership aims to save and improve lives and enable advanced care for people living with HIV.
Browse the full report of " Global Surface Protein gp 120 Market Size, Share & Trends Report by Type (DS-003, BMD-104, HNG-156, M-48U1, and Others) and by Application (Hospitals and Clinics) Forecast (2022-2028)" at https://www.omrglobal.com/industry-reports/surface-protein-gp-120-market
Moreover, in January 2021, ViiV Healthcare received US Food and Drug Administration (FDA) approval for the use of Canbenuva. Cabenuva is an injectable drug developed by ViiV Healthcare, used for the treatment of HIV infections in adults. Furthermore, in December 2020, Gilead Sciences Inc has announced the $1.4 million for Gilead Asia Pacific Rainbow Grant Program, in the Asia Pacific. This program aimed to improve the public-private partnerships in the Asia-Pacific region, to resolve the challenges faced by HIV-infected patients. Similarly, in September 2019, Merck Sharp & Dohme Corp (Merck &Co) has been granted US Food and Drug Administration (FDA) approval for Peifeltro and Delstrigo combination drugs. These combination drugs are used for the treatment of HIV Infection in Adults. Thus, key approvals, strategic collaborations, and grants are anticipated to drive the growth of the global surface protein gp 120 market over the forecast period (2022-2028)
Market Coverage
Segment Covered-
o By Type
o By Application
Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- GlaxoSmithKline Plc., ViiV Healthcare, Gilead services, Inc., and more among others
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Surface Protein gp 120 Market Report Segment
By Type
• DS-003
• BMD-104
• HNG-156
• M-48U1
By Application
Global Surface Protein gp 120 Market Report Segment by Region
North America
Europe
Rest of Europe
Asia-Pacific
Rest of the World